← Leaderboards

Radoslav Goldman

Georgetown University

Google Scholar ↗PubMed ↗ORCID ↗

$15,613,842

Attributed

$16,504,568

Total exposure

25

Grants

20

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY2005–23

$2M$1.5M$1M$500K$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

Funding mix

By agency

NIH$16,504,568 · 25

By mechanism

R01$8,099,975 · 3

U01$4,733,057 · 3

S10$2,070,139 · 3

R21$722,505 · 2

M01$526,685 · 12

R41$199,257 · 1

Top collaborators

Others in their field

Top investigators on “Proteins”

David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
Randall J Bateman · Washington University$187,292,085
Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
Reisa A. Sperling · Banner Health$145,046,481
Barton F Haynes · Duke University$136,029,850
Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280

Research focus

ProteinsSerumSamplingDetectionPrimary Carcinoma Of The Liver CellsDesignCirrhosisResourcesGlycoproteinsMalignant NeoplasmsEarly DiagnosisCancer PreventionSiteScreening For CancerPeptidesDisease ManagementPolysaccharidesStagingCase ControlPilot ProjectsGlycopeptidesLiver DiseasesGlycosylationRepository

Grant awards (55)

O-glycoproteins in the progression of liver disease$504,952

R01 · FY2023 · CA · contact PI

O-glycoproteins in the progression of liver disease$504,952

R01 · FY2022 · CA · contact PI

timsTOF Pro Mass Spectrometer$599,999

S10 · FY2021 · OD · contact PI

O-glycoproteins in the progression of liver disease$515,257

R01 · FY2021 · CA · contact PI

O-glycoproteins in the progression of liver disease$515,257

R01 · FY2020 · CA · contact PI

LC-MS Analysis of Site Specific Protein Glycoforms$470,482

U01 · FY2020 · CA · contact PI

O-glycoproteins in the progression of liver disease$515,257

R01 · FY2019 · CA · contact PI

LC-MS Analysis of Site Specific Protein Glycoforms$494,577

U01 · FY2019 · CA · contact PI

Glycans in Hepatocellular Carcinoma$395,634

R01 · FY2019 · CA · contact PI

Glycans in Hepatocellular Carcinoma$404,488

R01 · FY2018 · CA · contact PI

LC-MS Analysis of Site Specific Protein Glycoforms$295,450

U01 · FY2018 · CA · contact PI

Orbitrap Fusion Lumos ETD$1,088,814

S10 · FY2017 · OD · contact PI

Glycans in Hepatocellular Carcinoma$403,713

R01 · FY2017 · CA · contact PI

SULF2 in HNSCC$194,375

R21 · FY2017 · DE · contact PI

Alliance of Glycobiologists for Detection of Cancer$505,313

U01 · FY2016 · CA · contact PI

Glycans in Hepatocellular Carcinoma$403,705

R01 · FY2016 · CA · contact PI

Basic Cancer Research in Cancer Health Disparities$282,807

U01 · FY2016 · CA · contact PI

SULF2 in HNSCC$233,250

R21 · FY2016 · DE · contact PI

Glycans in Hepatocellular Carcinoma$417,481

R01 · FY2015 · CA · contact PI

Alliance of Glycobiologists for Detection of Cancer$366,151

U01 · FY2015 · CA · contact PI

Basic Cancer Research in Cancer Health Disparities$290,600

U01 · FY2015 · CA · contact PI

Alliance of Glycobiologists for Detection of Cancer$346,619

U01 · FY2014 · CA · contact PI

Basic Cancer Research in Cancer Health Disparities$282,030

U01 · FY2014 · CA · contact PI

5600 TripleTOF Mass Spectrometry$381,326

S10 · FY2013 · OD · contact PI

Glycans in Hepatocellular Carcinoma$368,497

R01 · FY2013 · CA · contact PI

Alliance of Glycobiologists for Detection of Cancer$353,401

U01 · FY2013 · CA · contact PI

Basic Cancer Research in Cancer Health Disparities$287,294

U01 · FY2013 · CA · contact PI

Glycans in Hepatocellular Carcinoma$392,840

R01 · FY2012 · CA · contact PI

Alliance of Glycobiologists for Detection of Cancer$387,871

U01 · FY2012 · CA · contact PI

Basic Cancer Research in Cancer Health Disparities$370,462

U01 · FY2012 · CA · contact PI

Glycans in Hepatocellular Carcinoma$393,651

R01 · FY2011 · CA · contact PI

Glycans in Hepatocellular Carcinoma$149,425

R01 · FY2011 · CA · contact PI

Glycans in Hepatocellular Carcinoma$406,276

R01 · FY2010 · CA · contact PI

Proteomic Analysis of Serum in Liver Cancer$346,147

R01 · FY2010 · CA · contact PI

Glycans in Hepatocellular Carcinoma$411,714

R01 · FY2009 · CA · contact PI

Proteomic Analysis of Serum in Liver Cancer$338,358

R01 · FY2009 · CA · contact PI

MOLECULAR EPIDEMIOLOGY OF HEAD AND NECK CANCER$3,452

M01 · FY2009 · RR · contact PI

Proteomic Analysis of Serum in Liver Cancer$340,569

R01 · FY2008 · CA · contact PI

Multiplex Electroluminescent Assay for Detection of Hepatocellular Carcinoma$199,257

R41 · FY2008 · CA

MOLECULAR EPIDEMIOLOGY OF HEAD AND NECK CANCER$64,923

M01 · FY2008 · RR · contact PI

MOLECULAR EPIDEMIOLOGY OF PROSTATE CANCER$37,099

M01 · FY2008 · RR · contact PI

Proteomic Analysis of Serum in Liver Cancer$371,802

R01 · FY2007 · CA · contact PI

MOLECULAR EPIDEMIOLOGY OF PROSTATE CANCER$125,222

M01 · FY2007 · RR · contact PI

MOLECULAR EPIDEMIOLOGY OF PROSTATE CANCER$87,734

M01 · FY2007 · RR · contact PI

Optimization of enrichment for MALDI TOF/TOF identification of cancer biomarkers$75,350

R03 · FY2007 · CA · contact PI

MOLECULAR EPIDEMIOLOGY OF HEAD AND NECK CANCER$43,867

M01 · FY2007 · RR · contact PI

MOLECULAR EPIDEMIOLOGY OF HEAD AND NECK CANCER$2,224

M01 · FY2007 · RR · contact PI

Optimization of enrichment for MALDI TOF/TOF identification of cancer biomarkers$77,600

R03 · FY2006 · CA · contact PI

MOLECULAR EPIDEMIOLOGY OF PROSTATE CANCER$47,498

M01 · FY2006 · RR · contact PI

MOLECULAR EPIDEMIOLOGY OF HEAD AND NECK CANCER$19,102

M01 · FY2006 · RR · contact PI

MOLECULAR EPIDEMIOLOGY OF HEAD AND NECK CANCER$37,859

M01 · FY2005 · RR

MOLECULAR EPIDEMIOLOGY OF PROSTATE CANCER$32,449

M01 · FY2005 · RR

Effects of smoking on ERb and AHR pathway in human lung$147,440

R21 · FY2004 · ES

Molecular epidemiology of head and neck cancer$25,256

M01 · FY2004 · RR

Effects of smoking on ERb and AHR pathway in human lung$147,440

R21 · FY2003 · ES